In short
In the realm of organ transplantation, researchers are constantly seeking innovative ways to improve patient outcomes and reduce the need for long-term immunosuppression. A groundbreaking clinical trial is currently underway, investigating the use of Donor Specific Immunomodulatory Cells (DSIMC) in liver transplant patients. This article delves into the details of this promising cell-based immunotherapy and its potential to revolutionize post-transplant care.
At a glance
- Trial Name
- Cell-based immunotherapy in solid organ transplantation to minimize systemic immunosuppression
- Investigational Drug
- Donor Specific Immunomodulatory Cells (DSIMC)
- Target Population
- Adult patients with end-stage liver disease undergoing liver transplantation
- Primary Objective
- Safety evaluation of DSIMC tolerance induction protocol
- Secondary Objective
- Determine percentage of patients achieving immunosuppression freedom at 36 months
- Administration
- Solution for injection via infusion
- Key Inclusion Criteria
- Age ≥18, WBC >2.0 x10^9 Cells/L, able to provide informed consent
- Key Exclusion Criteria
- Acute liver failure, total portal vein thrombosis, liver re-transplantation
What is DSIMC?
DSIMC, which stands for Donor Specific Immunomodulatory Cells, is an innovative cell-based therapy being developed for patients undergoing liver transplantation. This new treatment is designed to help patients with end-stage liver disease who are receiving a liver transplant from a deceased donor.
How DSIMC Works
DSIMC is a type of immunotherapy, which means it works with your body's immune system. The goal of this treatment is to help your body accept the new liver while reducing the need for strong immunosuppressive drugs that are typically used after transplantation. These cells are specifically designed to match the donor's characteristics, which is why they're called "donor-specific."
Potential Benefits of DSIMC
The main potential benefit of DSIMC is that it may allow patients to reduce or even stop taking immunosuppressive medications after their liver transplant. This is important because while these medications are necessary to prevent rejection of the new liver, they can have serious side effects when used long-term. By potentially reducing the need for these drugs, DSIMC aims to improve the quality of life for liver transplant recipients.
Current Clinical Trial
DSIMC is currently being studied in a clinical trial to evaluate its safety and effectiveness. The trial, named "Cell-based immunotherapy in solid organ transplantation to minimize systemic immunosuppression," is designed to include 18 patients. Here are some key points about the trial:
- It's specifically for patients with end-stage liver disease who are undergoing liver transplantation with a deceased donor organ.
- The main goal is to evaluate the safety of using DSIMC after liver transplantation.
- Researchers will also look at how many patients can stop taking immunosuppressive drugs 36 months after the transplant while maintaining good liver function.
Who is Eligible for the DSIMC Trial?
The trial has specific criteria for who can participate. Here are some of the main requirements:
- Patients must be adults (18 years or older)
- They must need a liver transplant from a deceased donor
- Their white blood cell count must be above a certain level (>2.0 x10^9 Cells/L)
- They must be able to understand the information provided and give written consent
Some conditions that would prevent a person from participating include:
- Having acute liver failure
- Complete blockage of the portal vein (a major blood vessel in the liver)
- Needing a second liver transplant
- Being pregnant or of childbearing age without a negative pregnancy test
- Participating in another interventional study
Safety Evaluation
The primary focus of this trial is to evaluate the safety of DSIMC. Researchers will closely monitor patients for 12 months after their liver transplant to ensure that the treatment is safe. This careful monitoring is a crucial part of developing any new medical treatment.
How DSIMC is Administered
DSIMC is given as a solution for injection. This means it's a liquid that's injected into the body, likely through an infusion. An infusion is when medication is given slowly through a vein, usually using an IV drip. This method allows the cells to enter the bloodstream and circulate throughout the body.